FLT3 and acute myeloid leukemia: Quizartinib alone exhibited limited inhibitory activity on the viability of primary human AML samples, unlike its effects observed in the FLT3-ITD cell lines MV-4-11 or MOLM13 (Fig. 4h, Fig. S2C).